Pregnancy and delivery outcomes following a pathological second trimester triple test screening result and a normal karyotype

References

• ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:217–227.
   PubMedGoogle Scholar
• Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886–894.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down’s syndrome. Health Technol Assess 1998;2:i–iv, 1.
   PubMedGoogle Scholar
• Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, et al.; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008;30:918–949.
   PubMedGoogle Scholar
• Cusick W, Rodis JF, Vintzileos AM, Albini SM, McMahon M, Campbell WA. Predicting pregnancy outcome from the degree of maternal serum alpha-fetoprotein elevation. J Reprod Med 1996;41:327–332.
   PubMed Web of Science ®Google Scholar
• Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1991;165:581–586.
   PubMed Web of Science ®Google Scholar
• Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Nørgaard-Pedersen B, Melbye M. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome(1). Obstet Gynecol 2001;97:277–282.
   PubMed Web of Science ®Google Scholar
• Hershkovitz R, Erez O, Sheiner E, Landau D, Mankuta D, Mazor M. Elevated maternal mid-trimester chorionic gonadotropin > or =4 MoM is associated with fetal cerebral blood flow redistribution. Acta Obstet Gynecol Scand 2003;82:22–27.
   PubMed Web of Science ®Google Scholar
• Lepage N, Chitayat D, Kingdom J, Huang T. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 2003;188:1354–1359.
   PubMed Web of Science ®Google Scholar
• Endres LK, Krotz S, Grobman WA. Isolated low second-trimester maternal serum beta-human chorionic gonadotropin is not associated with adverse pregnancy outcome. Am J Obstet Gynecol 2003;189:755–757.
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, et al.; FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260–267.
   PubMed Web of Science ®Google Scholar
• Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988;72:709–713.
   PubMed Web of Science ®Google Scholar
• Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP, Evans MI. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181:968–974.
   PubMed Web of Science ®Google Scholar
• Beta J, Bredaki FE, Rodriguez Calvo J, Akolekar R, Nicolaides KH. Maternal serum a-fetoprotein at 11-13 weeks’ gestation in spontaneous early preterm delivery. Fetal Diagn Ther 2011;30:88–93.
   PubMed Web of Science ®Google Scholar
• Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623–630.
   PubMed Web of Science ®Google Scholar
• Witters I, Legius E, Devriendt K, Moerman P, Van Schoubroeck D, Van Assche A, Fryns JP. Pregnancy outcome and long term prognosis in 868 children born after second trimester amniocentesis for maternal serum positive triple test screening and normal prenatal karyotype. J Med Genet 2001;38:336–338.
   PubMed Web of Science ®Google Scholar
• Chitayat D, Langlois S, Wilson RD; Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada; Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can 2011;33:736–750.
   PubMedGoogle Scholar
• Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, et al.; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001–2011.
   PubMed Web of Science ®Google Scholar
• Mikic TS, Johnson P. Second trimester maternal serum beta human chorionic gonadotrophin and pregnancy outcome. Br J Obstet Gynaecol 1999;106:598–600.
   PubMedGoogle Scholar
• Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005;25:949–953.
   PubMed Web of Science ®Google Scholar
• Canick JA, Knight GJ, Palomaki GE, Haddow JE. Second-trimester levels of maternal serum unconjugated oestriol and human chorionic gonadotropin in pregnancies affected by fetal anencephaly and open spina bifida. Prenat Diagn 1990;10:733–737.
   PubMed Web of Science ®Google Scholar